Regeneron Pharmaceuticals (NASDAQ:REGN) Sets New 1-Year Low After Analyst Downgrade

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)’s stock price reached a new 52-week low on Friday after Wells Fargo & Company lowered their price target on the stock from $1,050.00 to $900.00. Wells Fargo & Company currently has an overweight rating on the stock. Regeneron Pharmaceuticals traded as low as $691.00 and last traded at $698.34, with a volume of 492017 shares traded. The stock had previously closed at $733.59.

REGN has been the subject of several other reports. Canaccord Genuity Group lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, December 17th. BMO Capital Markets lowered their price objective on Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a research note on Friday, November 1st. Oppenheimer cut their target price on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 6th. Piper Sandler lowered their price target on Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Finally, StockNews.com downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. One research analyst has rated the stock with a sell rating, six have given a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $1,037.33.

Institutional Trading of Regeneron Pharmaceuticals

Several large investors have recently added to or reduced their stakes in REGN. Jacobs & Co. CA boosted its stake in shares of Regeneron Pharmaceuticals by 0.7% during the 4th quarter. Jacobs & Co. CA now owns 9,191 shares of the biopharmaceutical company’s stock worth $6,547,000 after acquiring an additional 64 shares during the last quarter. First Hawaiian Bank lifted its position in Regeneron Pharmaceuticals by 18.8% during the fourth quarter. First Hawaiian Bank now owns 2,995 shares of the biopharmaceutical company’s stock valued at $2,133,000 after purchasing an additional 474 shares in the last quarter. Range Financial Group LLC bought a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at about $220,000. Diversified Trust Co grew its holdings in Regeneron Pharmaceuticals by 93.0% during the fourth quarter. Diversified Trust Co now owns 2,330 shares of the biopharmaceutical company’s stock valued at $1,660,000 after purchasing an additional 1,123 shares during the period. Finally, Nordea Investment Management AB increased its position in Regeneron Pharmaceuticals by 23.6% in the fourth quarter. Nordea Investment Management AB now owns 42,667 shares of the biopharmaceutical company’s stock worth $30,160,000 after buying an additional 8,135 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Price Performance

The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The stock has a market cap of $76.58 billion, a P/E ratio of 17.25, a P/E/G ratio of 2.19 and a beta of 0.10. The firm has a 50 day moving average price of $751.44 and a 200 day moving average price of $961.82.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.